# Bradykinin Mediated Angioedema Market

> Bradykinin Mediated Angioedema Market Research Report By Type (Hereditary Angioedema, Acquired Angioedema, Idiopathic Angioedema), By Treatment Options (C1-Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kalinate Therapy, Antifibrinolytic Agents), By Route of Administration (Subcutaneous, Intravenous, Oral), By Patient Demographics (Pediatric Patients, Adult Patients, Geriatric Patients) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.62%
- **2024:** $ 1.15 Billion
- **2025:** $ 1.29 Billion
- **2035:** $ 3.87 Billion
- **Key Players:** Takeda Pharmaceutical Company Limited (JP), CSL Behring LLC (US), Pharming Group N.V. (NL), Sobi AB (SE), BioCryst Pharmaceuticals, Inc. (US), Eisai Co., Ltd. (JP), Grifols S.A. (ES), Amgen Inc. (US)

**Report ID:** MRFR/HC/34260-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** August 11, 2026

**URL:** https://www.marketresearchfuture.com/reports/bradykinin-mediated-angioedema-market-36162

---

## Market Summary

## **Bradykinin Mediated Angioedema Market Overview**

As per MRFR analysis, the Bradykinin Mediated Angioedema Market Size was estimated at 1.15 (USD Billion) in 2024. The Bradykinin Mediated Angioedema Market Industry is expected to grow from 1.29 (USD Billion) in 2025 to 3.47 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 11.62% during the forecast period (2025 - 2034).

### **Key Bradykinin Mediated Angioedema Market Trends Highlighted**

The Bradykinin Mediated Angioedema Market is significantly influenced by several key market drivers. An increasing awareness of the disorder has led to a rise in early diagnosis and treatment options. Enhancements in medical research have improved the understanding of angioedema, promoting the development of targeted therapies. Additionally, the growing prevalence of underlying conditions such as hereditary angioedema and increased access to healthcare services are facilitating market expansion. Pharmaceutical advancements are also pushing the boundaries of treatment modalities, further driving the market. Opportunities in this market are abundant, particularly in the development of innovative therapies and products targeting various patient demographics.

The rise of personalized medicine opens new avenues for customized treatment solutions. Collaborations between pharmaceutical companies and research institutions can accelerate drug discovery processes. Expanding geographical presence in emerging markets represents another significant opportunity, as these regions often have unmet medical needs and a growing patient population. The establishment of educational programs focused on angioedema can help in raising awareness, leading to better patient outcomes and market growth. In recent times, there has been a noticeable trend towards the development of biologic drugs, which are showing promise in effectively managing symptoms of bradykinin-mediated angioedema.

Advancements in biotechnology are contributing to this trend, along with a shift toward chronic disease management models. Digital health solutions, including telemedicine and mobile applications for monitoring symptoms, are gaining traction. These trends indicate a shift in how healthcare is delivered, making it more accessible and patient-centered. As the market evolves, these dynamics will likely shape its future direction, offering new potential pathways for growth and innovation.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Bradykinin Mediated Angioedema Market Drivers**

### **Increasing Awareness and Diagnosis of Bradykinin Mediated Angioedema**

As the prevalence of bradykinin mediated angioedema becomes more recognized, both healthcare providers and patients are gaining a better understanding of this condition. There has been an evident shift towards improving diagnosis rates, identifying symptoms early, and advocating for timely treatment. Enhanced education and awareness campaigns from health organizations contribute significantly to this shift. As medical professionals become more informed about the various manifestations of angioedema, they are better equipped to identify bradykinin mediated cases.

This growing awareness extends to patients, who are increasingly educated about their conditions through support groups, online resources, and healthcare platforms. Consequently, more individuals are seeking medical advice, leading to a higher rate of diagnosis and treatment. This trend is a crucial driver for the Bradykinin Mediated Angioedema Market Industry as it translates into increased demand for healthcare services, diagnostic tools, and effective therapies.

With more patients being diagnosed, pharmaceutical companies are prompted to invest in the development of specialized medications, further fueling market growth. The heightened focus on research and development to understand the pathophysiological mechanisms underlying this condition is also pivotal. Importantly, as more advancements are made in treatments, physicians are likely to prescribe these innovative solutions, which will be highly beneficial for patient outcomes.

Thus, increasing awareness not only plays a key role in patient diagnosis but also drives the innovation and growth of the Bradykinin Mediated Angioedema Market Industry, fostering a cycle that enhances overall healthcare standards and improves life quality for patients experiencing this condition.

### **Technological Advancements in Pharmaceutical Development**

The Bradykinin Mediated Angioedema Market Industry is significantly benefiting from profound advancements in technology, particularly in pharmaceutical research and product development. Innovations in biotechnology and drug formulation techniques have led to the introduction of more effective treatments for bradykinin mediated angioedema, enhancing patient care. The development of monoclonal antibodies, small molecules, and new biologics specifically targeting the underlying mechanisms of bradykinin release exemplifies the forward momentum in this field.

Furthermore, improved drug delivery systems are ensuring better patient compliance and therapeutic outcomes, making these treatments more accessible and efficient. Such technological breakthroughs are vital in expanding the available treatment options, which, in turn, supports the growth of the Bradykinin Mediated Angioedema Market.

### **Rising Incidence of Angioedema Cases**

The growing incidence of angioedema cases globally is a major driver for the Bradykinin Mediated Angioedema Market Industry. Factors such as environmental changes, dietary habits, and increased exposure to allergens contribute to the rise in cases. This upward trend necessitates enhanced healthcare initiatives, expanding the market for targeted therapies and treatments for patients suffering from this condition. As more individuals experience symptoms and seek medical assistance, healthcare providers are more inclined to focus on providing effective solutions, leading to market growth.

## ** ****Bradykinin Mediated Angioedema Market Segment Insights**

### **Bradykinin Mediated Angioedema Market Type Insights**

The Bradykinin Mediated Angioedema Market is witnessing significant growth, with a market valuation of 0.93 USD Billion in 2023 and expected to reach 2.5 USD Billion by 2032, driven by rising awareness and improved diagnostics. The market segmentation around Type prominently features Hereditary Angioedema, Acquired Angioedema, and Idiopathic Angioedema. Among these, [Hereditary Angioedema](../../../reports/hereditary-angioedema-therapeutics-market-12163) holds a majority market share, valued at 0.4 USD Billion in 2023, and is projected to grow substantially to 1.05 USD Billion by 2032, highlighting its dominance due to genetic predispositions and increasing patient identification.

This sub-segment is particularly significant as it emphasizes the need for targeted therapies and ongoing patient management strategies. Acquired Angioedema, while smaller in comparison, reflects a substantial market presence, with a valuation of 0.3 USD Billion in 2023 and expected growth to 0.8 USD Billion by 2032. The challenges surrounding the identification of triggers and underlying conditions contribute to its relevance in the market, making the development of therapeutic options increasingly important. Lastly, Idiopathic Angioedema, which accounted for 0.23 USD Billion in 2023 and aims for a future valuation of 0.65 USD Billion, is the least dominant type.

However, it presents unique challenges due to its unpredictable nature, leading to a notable opportunity for pharmaceutical advancements and improved treatment strategies. The Bradykinin Mediated Angioedema Market data reflects a balanced yet complex interplay of these segments, with varying growth drivers, including heightened research initiatives and patient advocacy groups fostering a conducive environment for market expansion. Understanding this market segmentation allows stakeholders to tailor their approaches to meet the varying needs of each type effectively while capitalizing on the growth potential and complexities inherent in the treatment landscape.

As such, the industry faces opportunities and challenges that influence the development of effective therapies tailored for specific Angioedema types, ensuring that patient outcomes continue to improve as the market evolves.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Bradykinin Mediated Angioedema Market Treatment Options Insights**

The Bradykinin Mediated Angioedema Market, focusing on Treatment Options, shows a robust growth trajectory, with the market valued at 0.93 billion USD in 2023. By 2032, this market is expected to grow significantly. The Treatment Options segment is driven by an increasing prevalence of Bradykinin Mediated Angioedema, with key therapies such as C1-Inhibitor Replacement Therapy playing a pivotal role owing to its effectiveness in managing acute attacks. Bradykinin B2 Receptor Antagonists are also essential, showcasing a significant demand due to their targeted action in slowing down symptoms related to angioedema.

Additionally, Kalinate Therapy is garnering attention as it presents opportunities for enhanced patient outcomes. Antifibrinolytic Agents remain crucial within this market, offering therapeutic benefits that complement other treatment modalities. Overall, the Bradykinin Mediated Angioedema Market revenue illustrates a clear alignment between growing treatment needs and innovative drug development strategies, emphasizing the importance of each therapy in providing effective management of the disorder amidst evolving patient care standards.

### **Bradykinin Mediated Angioedema Market Route of Administration Insights**

The Bradykinin Mediated Angioedema Market is experiencing significant growth, particularly in the Route of Administration segment, which plays a critical role in treatment efficacy and patient compliance. In 2023, the market was valued at 0.93 billion USD and is projected to expand substantially in the coming years. The market sees a strong emphasis on various methods of administration, including Subcutaneous, Intravenous, and Oral, each catering to different patient needs. Subcutaneous administration is noted for its ease of use and ability to improve patient adherence, making it a preferred choice among healthcare providers.

Intravenous administration, albeit less common, offers rapid action for acute cases and is vital in clinical settings. The Oral route, with its convenience and patient-friendly nature, continues to gain traction, appealing particularly to home care settings. These various routes contribute to the segmentation of the Bradykinin Mediated Angioedema Market, which is crucial for targeted therapies tailored to individual patient profiles. The growth in this segment is driven by an increasing prevalence of bradykinin-mediated conditions, evolving treatment paradigms, and ongoing research into improving administration methods while enhancing patient experience and outcomes.

The Bradykinin Mediated Angioedema Market data reveals promising trends around these administration routes, highlighting their potential to meet diverse healthcare needs.

### **Bradykinin Mediated Angioedema Market Patient Demographics Insights**

The Bradykinin Mediated Angioedema Market, valued at 0.93 billion USD in 2023, showcases a diverse Patient Demographics segment that includes Pediatric, Adult, and Geriatric Patients. Each group presents unique needs and characteristics, playing a crucial role in shaping the overall market dynamics. Pediatric Patients often face challenges with diagnosis and treatment adherence, making this demographic vital for future treatment innovations. Meanwhile, Adult Patients typically dominate the market due to the higher prevalence of bradykinin-mediated conditions within this age group, driven by lifestyle factors and genetic predispositions.

The Geriatric Patients segment is also significant as it is increasingly impacted by this condition alongside age-related health issues, creating a demand for tailored therapeutic solutions. These demographics collectively contribute to the Bradykinin Mediated Angioedema Market growth as the industry responds to their specific treatment requirements and associated healthcare trends. Overall, the market exhibits a steady increase in interest and investment, emphasizing the importance of understanding these patient segments for future strategies and developments in the industry.With an expected continued expansion, the market is poised to address escalating healthcare needs responsibly and effectively.

### **Bradykinin Mediated Angioedema Market Regional Insights**

The Bradykinin Mediated Angioedema Market revenue is witnessing substantial growth across different regions, with North America holding a significant market share of 0.42 USD Billion in 2023, projected to increase to 1.05 USD Billion by 2032. This dominance can be attributed to advanced healthcare infrastructure and a high prevalence of angioedema cases. Europe follows as another key region, with market values of 0.25 USD Billion in 2023 and 0.65 USD Billion in 2032, benefiting from a strong regulatory framework and research initiatives.

The APAC region, though smaller, shows promising growth potential, escalating from 0.15 USD Billion in 2023 to 0.45 USD Billion by 2032, driven by rising healthcare awareness and investments in treatment options.

South America and MEA represent the emerging markets in the Bradykinin Mediated Angioedema Market industry, with values of 0.06 USD Billion and 0.05 USD Billion in 2023, respectively, reflecting a growth trajectory as healthcare access improves. These regions present significant opportunities to tap into increasing demand for effective treatments as more awareness of this condition grows. Bradykinin Mediated Angioedema Market statistics indicate a clear trend toward increased investments, highlighting the importance of continuously expanding healthcare access and innovation across these diverse regions.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Bradykinin Mediated Angioedema Market Key Players and Competitive Insights**

The Bradykinin Mediated Angioedema Market is characterized by a dynamic competitive landscape, driven by the increasing prevalence of angioedema conditions and the growing understanding of bradykinin's role in these diseases. As research advances, companies are focusing on the development of innovative therapeutic options that cater to the specific needs of patients suffering from angioedema. 

The market includes a variety of stakeholders ranging from pharmaceutical giants to specialized biotechnology firms, all vying for a significant share. Companies are employing strategies such as collaborations, mergers, and acquisitions to enhance their product portfolios and extend their market reach. The landscape is also marked by intense competition where product differentiation and effective marketing strategies play crucial roles in capturing consumer attention.

Takeda Pharmaceutical Company holds a prominent position in the Bradykinin Mediated Angioedema Market, showcasing its strengths through a robust pipeline of products and research initiatives targeted specifically at treating angioedema. The company is recognized for its commitment to patient-centric solutions, which is reflected in its innovative approaches to treatment development. Takeda's strategy emphasizes the importance of addressing patient needs and improving health outcomes, enabling it to maintain a competitive edge in the market. 

Additionally, its extensive network and experience in managing complex therapeutic areas bolster its operational capabilities and market presence. By investing in research and development, Takeda continually seeks to enhance its therapeutic offerings, solidifying its reputation in the bradykinin-mediated angioedema segment.

Novo Nordisk has also established itself as a key player in the Bradykinin Mediated Angioedema Market, bringing valuable expertise and resources to the table. The company is known for its strong focus on innovation, particularly in developing effective therapies that manage rare and chronic conditions like bradykinin-mediated angioedema. Novo Nordisk adopts a holistic approach to treatment by incorporating advancements in biotechnology and leveraging its extensive knowledge of patient care. Its commitment to research allows for the continuous evolution of its product offerings, positioning the company effectively against its competitors. 

Furthermore, Novo Nordisk's strategic partnerships and collaborations enhance its ability to introduce novel solutions to the market, ensuring it meets the demands and needs of patients suffering from angioedema in an increasingly competitive environment.

### **Key Companies in the Bradykinin Mediated Angioedema Market Include**

- Takeda Pharmaceutical Company
- Novo Nordisk
- Biocryst Pharmaceuticals
- GSK
- Bayer AG
- Pfizer Inc
- CSL Limited
- [**Amgen Inc**](https://www.amgen.com/products)
- Regeneron Pharmaceuticals
- Roche Holding AG
- Eli Lilly and Company
- Merck and Co
- Sanofi
- AstraZeneca
- Shire plc

## Bradykinin Mediated Angioedema Market Industry Developments

- **Q2 2025: Pharvaris Presents Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025** Pharvaris presented new clinical data on deucrictibant, an oral bradykinin B2 receptor antagonist, at the EAACI Congress 2025, showing significant attack reduction and improved quality of life for hereditary angioedema patients. The company also announced advancement into Phase 3 trials for both prophylactic and on-demand treatment indications.
- **Q2 2025: Pharvaris AGM 2025: A Pivotal Moment for Braking into the Angioedema Market** Pharvaris N.V. announced that its lead drug candidate, deucrictibant, is approaching pivotal clinical readouts and regulatory milestones, with the company preparing for its June 27, 2025 Annual General Meeting. The oral therapy targets both hereditary and acquired bradykinin-mediated angioedema, with Phase 3 trials underway.
- **Q1 2025: Pharvaris Outlines 2025 Strategic Priorities** Pharvaris announced the initiation of CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema attacks, and confirmed ongoing preparations for regulatory submission and commercialization pending trial results.

## **Bradykinin Mediated Angioedema Market Segmentation Insights**

### **Bradykinin Mediated Angioedema Market Type Outlook**

- Hereditary Angioedema
- Acquired Angioedema
- Idiopathic Angioedema

### **Bradykinin Mediated Angioedema Market Treatment Options Outlook**

- C1-Inhibitor Replacement Therapy
- Bradykinin B2 Receptor Antagonists
- Kalinate Therapy
- Antifibrinolytic Agents

### **Bradykinin Mediated Angioedema Market Route of Administration Outlook**

- Subcutaneous
- Intravenous
- Oral

### **Bradykinin Mediated Angioedema Market Patient Demographics Outlook**

- Pediatric Patients
- Adult Patients
- Geriatric Patients

### **Bradykinin Mediated Angioedema Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Increased Research Funding

The allocation of research funding for bradykinin mediated angioedema is a critical driver for the Bradykinin Mediated Angioedema Market. Government and private organizations are increasingly investing in studies aimed at understanding the underlying mechanisms of angioedema and developing effective treatments. This influx of funding is expected to accelerate the pace of innovation, leading to the discovery of new therapeutic agents. Furthermore, as research progresses, the identification of novel biomarkers may enhance diagnostic accuracy and treatment efficacy. The commitment to advancing knowledge in this field is likely to bolster the growth trajectory of the Bradykinin Mediated Angioedema Market.

### Rising Incidence of Angioedema

The increasing prevalence of bradykinin mediated angioedema is a notable driver for the Bradykinin Mediated Angioedema Market. Recent studies indicate that the incidence of hereditary angioedema is approximately 1 in 50,000 individuals, while acquired forms are becoming more recognized. This rise in cases necessitates effective treatment options, thereby propelling market growth. As awareness of the condition expands, healthcare providers are more likely to diagnose and treat patients, further contributing to the market's expansion. The growing patient population is expected to drive demand for innovative therapies, which may lead to increased investments in research and development within the Bradykinin Mediated Angioedema Market.

### Growing Patient Advocacy Groups

The emergence of patient advocacy groups dedicated to bradykinin mediated angioedema is fostering awareness and support within the Bradykinin Mediated Angioedema Market. These organizations play a pivotal role in educating patients and healthcare professionals about the condition, thereby promoting timely diagnosis and treatment. Their efforts in raising awareness can lead to increased demand for therapies, as more individuals seek medical assistance. Additionally, these groups often collaborate with pharmaceutical companies to facilitate clinical trials, which can expedite the development of new treatments. The influence of patient advocacy is likely to enhance the visibility of the Bradykinin Mediated Angioedema Market.

### Advancements in Therapeutic Options

Innovations in therapeutic approaches for bradykinin mediated angioedema are significantly influencing the Bradykinin Mediated Angioedema Market. The introduction of novel therapies, such as C1-inhibitor replacement therapies and bradykinin receptor antagonists, has transformed treatment paradigms. These advancements not only improve patient outcomes but also enhance the overall market landscape. For instance, the approval of new drugs has led to a surge in treatment options, catering to diverse patient needs. As the market continues to evolve, the development of targeted therapies is likely to attract further investment, thereby fostering growth within the Bradykinin Mediated Angioedema Market.

### Regulatory Incentives for Drug Development

Regulatory bodies are increasingly providing incentives for the development of treatments for bradykinin mediated angioedema, which serves as a significant driver for the Bradykinin Mediated Angioedema Market. Initiatives such as orphan drug designations and fast-track approvals are designed to encourage pharmaceutical companies to invest in this niche market. These regulatory frameworks not only reduce the time and cost associated with bringing new therapies to market but also enhance the attractiveness of the sector for investors. As more companies enter the market, the competitive landscape is likely to evolve, leading to a broader array of treatment options for patients suffering from bradykinin mediated angioedema.

## Future Outlook

The Bradykinin Mediated Angioedema Market is projected to grow at 11.62% CAGR from 2025 to 2035, driven by increasing awareness, innovative therapies, and rising patient populations.

**New opportunities:**

- Development of targeted biologics for personalized treatment plans. Expansion of telehealth services for remote patient monitoring. Investment in educational programs for healthcare professionals on angioedema management.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in innovative therapeutic solutions.

## Segment Insights

### By Type: Hereditary Angioedema (Largest) vs. Acquired Angioedema (Fastest-Growing)

In the Bradykinin Mediated Angioedema Market, the distribution of market share among the different types of angioedema reveals a significant predominance of Hereditary Angioedema. This segment continues to hold the largest market share due to the increasing awareness and diagnosis rates among populations, coupled with advancements in treatment options tailored for hereditary conditions. Contrarily, Acquired Angioedema is rapidly emerging, gaining traction among healthcare providers owing to a growing recognition of its different etiologies and triggers, leading to expanded research and treatment opportunities.

Hereditary Angioedema (Dominant) vs. Acquired Angioedema (Emerging)

Hereditary Angioedema remains the dominant segment within the Bradykinin Mediated Angioedema Market due to its hereditary nature and well-established treatment protocols, including specific therapies that cater to this chronic condition. Patients often require long-term management to prevent attacks, which sustains the demand for specialized treatments. On the other hand, Acquired Angioedema is emerging as a significant segment driven by heightened clinical understanding and diagnosis of the condition. The growing number of cases attributed to various factors such as medications or associated diseases is prompting healthcare systems to focus more on tailored interventions for acquired cases, thus shaping a competitive landscape that favors innovative therapy development.

### By Treatment Options: C1-Inhibitor Replacement Therapy (Largest) vs. Bradykinin B2 Receptor Antagonists (Fastest-Growing)

In the Bradykinin Mediated Angioedema Market, the market share distribution reveals that C1-Inhibitor Replacement Therapy stands as the largest segment, accounting for a substantial portion of the overall market. This established position is driven by its efficacy in restoring C1 inhibitor levels, making it a preferred choice among clinicians and patients. On the other hand, Bradykinin B2 Receptor Antagonists are rapidly gaining traction, emerging as the fastest-growing treatment option due to their novel mechanism targeting bradykinin receptors directly, thereby attracting interest from both medical professionals and pharmaceutical companies. The growth trends within this segment are remarkably influenced by increasing awareness of Bradykinin Mediated Angioedema Market and innovative treatment approaches. Factors such as the rising incidence of angioedema, advancements in drug formulations, and expanding clinical trials for new therapies are contributing to the growth of both existing and emerging treatment options. The expansion of treatment protocols and supportive guidelines aimed at improving patient outcomes further encourages the adoption of these therapies in clinical practice.

C1-Inhibitor Replacement Therapy (Dominant) vs. Bradykinin B2 Receptor Antagonists (Emerging)

C1-Inhibitor Replacement Therapy is recognized as the dominant treatment option in the Bradykinin Mediated Angioedema Market due to its long-standing use and established efficacy. It effectively replaces the deficient C1 inhibitor in patients, addressing the underlying cause of the condition. This treatment is often preferred in acute and prophylactic settings, making it a mainstay in therapeutic regimens. Conversely, Bradykinin B2 Receptor Antagonists represent an emerging treatment class that targets bradykinin receptors, offering a different mode of action. Their rapid development underscores the growing interest in targeted therapies and provides a potential alternative for patients who may not respond adequately to traditional therapies. The ongoing research and clinical trials are expected to enhance their market presence significantly in the coming years.

### By Route of Administration: Subcutaneous (Largest) vs. Intravenous (Fastest-Growing)

In the Bradykinin Mediated Angioedema Market, the route of administration plays a pivotal role in treatment preference and efficacy. Subcutaneous administration currently holds the largest share due to its ease of use, patient compliance, and effective delivery of therapeutics. Intravenous administration, although lower in share, is gaining traction due to its rapid onset of action, especially in acute scenarios, catering to a segment of patients with severe manifestations.

Administration Method: Subcutaneous (Dominant) vs. Intravenous (Emerging)

The subcutaneous route for administering treatments in the Bradykinin Mediated Angioedema Market remains dominant, as it offers patients an easier, less invasive option that fits well with home-use scenarios. This method allows individuals to manage their condition with minimal professional supervision. On the other hand, intravenous administration is emerging as a significant alternative, particularly for patients requiring immediate relief in acute angioedema episodes. This method ensures that medications are delivered rapidly into the bloodstream, resulting in quicker effectiveness, which is critical for life-threatening situations.

### By Patient Demographics: Adult Patients (Largest) vs. Pediatric Patients (Fastest-Growing)

In the Bradykinin Mediated Angioedema Market, the demographic distribution reveals that adult patients constitute the largest segment, reflecting their higher prevalence of chronic conditions that can lead to this type of angioedema. Meanwhile, pediatric patients represent the fastest-growing segment due to increasing awareness and improved diagnosis of bradykinin-mediated conditions in younger populations, alongside enhanced treatment options available for children. As healthcare providers focus on early interventions, the pediatric segment is seeing a significant uptick in reported cases. The growth is also fueled by advocacy for better health insights for children, along with greater engagement in research dedicated to understanding angioedema in pediatric populations. This shift highlights the importance of tailored treatment approaches for diverse age groups in managing this condition.

Adult Patients (Dominant) vs. Geriatric Patients (Emerging)

Adult patients dominate the Bradykinin Mediated Angioedema Market, primarily due to their higher susceptibility and existing health conditions that can exacerbate angioedema symptoms. The adult demographic qualifies as the main focus of pharmaceutical developments, where advancements in treatments cater extensively to their needs. In contrast, geriatric patients emerge as an important demographic, driven by the aging population and related health complexities. While they may represent a smaller market share currently, the growing recognition of atypical angioedema challenges and the need for specialized treatment options for the elderly are likely to bolster their market presence. As medical research evolves, tailored therapies for geriatric patients will become pivotal, addressing unique responses and interactions associated with aging.

## Regional Market Share Analysis

### North America : Leading Market for Treatments

North America is the largest market for Bradykinin Mediated Angioedema Market, accounting for approximately 60% of the global market share. The region's growth is driven by increasing awareness of the condition, advancements in treatment options, and supportive regulatory frameworks. The FDA's approval of new therapies has catalyzed market expansion, with a growing demand for effective management solutions. The United States is the primary contributor, with significant investments from key players like Takeda Pharmaceutical Company Limited and BioCryst Pharmaceuticals, Inc. Canada also plays a vital role, focusing on improving healthcare access and treatment options. The competitive landscape is characterized by a mix of established companies and emerging players, fostering innovation and collaboration in the sector.

### Europe : Emerging Market with Potential

Europe is witnessing a significant rise in the Bradykinin Mediated Angioedema Market, holding approximately 25% of the global share. The region's growth is fueled by increasing patient awareness, advancements in biotechnology, and supportive healthcare policies. Regulatory bodies are actively promoting research and development, which is expected to enhance treatment availability and accessibility across member states. Leading countries such as Germany, France, and the UK are at the forefront, with a robust presence of key players like Pharming Group N.V. and Sobi AB. The competitive landscape is evolving, with collaborations between pharmaceutical companies and research institutions aimed at developing innovative therapies. The European Medicines Agency continues to support initiatives that enhance treatment options for patients.

### Asia-Pacific : Rapidly Evolving Healthcare Sector

The Asia-Pacific region is emerging as a significant player in the Bradykinin Mediated Angioedema Market, accounting for about 10% of the global share. The growth is driven by increasing healthcare expenditure, rising awareness of rare diseases, and the introduction of innovative therapies. Countries like Japan and Australia are leading the charge, supported by favorable regulatory environments that encourage research and development in this area. Japan is home to key players such as Eisai Co., Ltd., while Australia is witnessing a surge in clinical trials and partnerships aimed at enhancing treatment options. The competitive landscape is characterized by a mix of local and international companies, fostering a collaborative environment for innovation. As the region continues to develop, the demand for effective management solutions is expected to rise significantly.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is currently the smallest market for Bradykinin Mediated Angioedema Market, holding approximately 5% of the global share. However, the region presents untapped opportunities for growth, driven by increasing healthcare investments and a rising prevalence of rare diseases. Governments are beginning to recognize the importance of addressing these conditions, leading to improved healthcare policies and funding for research initiatives. Countries like South Africa and the UAE are emerging as key players in the market, with a growing interest from international pharmaceutical companies. The competitive landscape is still developing, with local firms collaborating with global entities to enhance treatment availability. As awareness increases, the demand for effective therapies is expected to grow, paving the way for future market expansion.

## Competitive Benchmarking

The Bradykinin Mediated Angioedema Market is characterized by a dynamic competitive landscape, driven by increasing awareness of the condition and advancements in therapeutic options. Key players such as Takeda Pharmaceutical Company Limited (Japan), BioCryst Pharmaceuticals, Inc. (US), and Pharming Group N.V. (Netherlands) are at the forefront, each adopting distinct strategies to enhance their market presence. Takeda (Japan) focuses on innovation through the development of novel therapies, while BioCryst Pharmaceuticals, Inc. (US) emphasizes strategic partnerships to bolster its research capabilities. Pharming Group N.V. (Netherlands) appears to be concentrating on expanding its global footprint, particularly in emerging markets, thereby shaping a competitive environment that is increasingly collaborative yet fiercely competitive.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure is moderately fragmented, with a mix of established players and emerging biotech firms. This fragmentation allows for diverse approaches to treatment and patient care, while the collective influence of key players drives innovation and competitive differentiation.

In August  Takeda Pharmaceutical Company Limited (Japan) announced a strategic collaboration with a leading research institution to accelerate the development of its next-generation therapies for angioedema. This partnership is likely to enhance Takeda's research capabilities and expedite the introduction of innovative treatments, positioning the company as a leader in the therapeutic landscape.

In September  BioCryst Pharmaceuticals, Inc. (US) launched a new digital platform aimed at improving patient engagement and adherence to treatment protocols. This initiative not only reflects the company's commitment to patient-centric care but also indicates a broader trend towards digital transformation in the healthcare sector, which may enhance treatment outcomes and patient satisfaction.

In July  Pharming Group N.V. (Netherlands) secured regulatory approval for its latest product aimed at treating hereditary angioedema, marking a significant milestone in its product pipeline. This approval is expected to strengthen Pharming's market position and expand its therapeutic offerings, potentially increasing its share in the competitive landscape.

As of October  current trends in the Bradykinin Mediated Angioedema Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing supply chain reliability. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements and innovative treatment solutions, underscoring the importance of agility and responsiveness in a rapidly changing market.

## Recent News & Developments

- **Q2 2025: Pharvaris Presents Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025** Pharvaris presented new clinical data on deucrictibant, an oral bradykinin B2 receptor antagonist, at the EAACI Congress 2025, showing significant attack reduction and improved quality of life for hereditary angioedema patients. The company also announced advancement into Phase 3 trials for both prophylactic and on-demand treatment indications.
- **Q2 2025: Pharvaris AGM 2025: A Pivotal Moment for Braking into the Angioedema Market** Pharvaris N.V. announced that its lead drug candidate, deucrictibant, is approaching pivotal clinical readouts and regulatory milestones, with the company preparing for its June 27, 2025 Annual General Meeting. The oral therapy targets both hereditary and acquired bradykinin-mediated angioedema, with Phase 3 trials underway.
- **Q1 2025: Pharvaris Outlines 2025 Strategic Priorities** Pharvaris announced the initiation of CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema attacks, and confirmed ongoing preparations for regulatory submission and commercialization pending trial results.

## Report Scope

| MARKET SIZE 2024 | 1.154(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.288(USD Billion) |
| MARKET SIZE 2035 | 3.868(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.62% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Takeda Pharmaceutical Company Limited (JP), CSL Behring LLC (US), Pharming Group N.V. (NL), Sobi AB (SE), BioCryst Pharmaceuticals, Inc. (US), Eisai Co., Ltd. (JP), Grifols S.A. (ES), Amgen Inc. (US) |
| Segments Covered | Type, Treatment Options, Route of Administration, Patient Demographics, Regional |
| Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance treatment options in the Bradykinin Mediated Angioedema Market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the Bradykinin Mediated Angioedema market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for Bradykinin Mediated Angioedema by 2035?**
A: The projected market valuation for Bradykinin Mediated Angioedema is expected to reach 3.868 USD Billion by 2035.

**Q: What was the market valuation for Bradykinin Mediated Angioedema in 2024?**
A: The market valuation for Bradykinin Mediated Angioedema was 1.154 USD Billion in 2024.

**Q: What is the expected CAGR for the Bradykinin Mediated Angioedema Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Bradykinin Mediated Angioedema Market during the forecast period 2025 - 2035 is 11.62%.

**Q: Which companies are key players in the Bradykinin Mediated Angioedema Market?**
A: Key players in the Bradykinin Mediated Angioedema Market include Takeda Pharmaceutical Company Limited, CSL Behring LLC, and Pharming Group N.V.

**Q: What are the main types of angioedema segments in the market?**
A: The main types of angioedema segments include Hereditary Angioedema, Acquired Angioedema, and Idiopathic Angioedema.

**Q: What was the market size for Hereditary Angioedema in 2024?**
A: The market size for Hereditary Angioedema was 0.462 USD Billion in 2024.

**Q: What treatment options are available for Bradykinin Mediated Angioedema?**
A: Available treatment options include C1-Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, and Antifibrinolytic Agents.

**Q: What is the projected market size for C1-Inhibitor Replacement Therapy by 2035?**
A: The projected market size for C1-Inhibitor Replacement Therapy is expected to reach 1.577 USD Billion by 2035.

**Q: How does the route of administration impact the Bradykinin Mediated Angioedema Market?**
A: The route of administration includes Subcutaneous, Intravenous, and Oral, with Subcutaneous expected to reach 1.615 USD Billion by 2035.

**Q: What demographic segments are considered in the Bradykinin Mediated Angioedema Market?**
A: Demographic segments include Pediatric Patients, Adult Patients, and Geriatric Patients, with Adult Patients projected to reach 1.949 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/bradykinin-mediated-angioedema-market-36162*